Reich K, Thyssen JP, Blauvelt A, Eyerich K, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet 2022;400:273-282.
PMID: 35871814